Cite
Secondary histiocytic sarcoma with BRAFV600E mutation responsive to MAPK‐targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR‐targeted therapy.
MLA
Venkataraman, Vinayak, et al. “Secondary Histiocytic Sarcoma with BRAFV600E Mutation Responsive to MAPK‐targeted Therapy Presenting with Recurrence with MTOR Mutation Responsive to MTOR‐targeted Therapy.” Pediatric Blood & Cancer, vol. 68, no. 10, Oct. 2021, pp. 1–3. EBSCOhost, https://doi.org/10.1002/pbc.29166.
APA
Venkataraman, V., Massoth, L. R., Sullivan, R. J., & Friedmann, A. M. (2021). Secondary histiocytic sarcoma with BRAFV600E mutation responsive to MAPK‐targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR‐targeted therapy. Pediatric Blood & Cancer, 68(10), 1–3. https://doi.org/10.1002/pbc.29166
Chicago
Venkataraman, Vinayak, Lucas R. Massoth, Ryan J. Sullivan, and Alison M. Friedmann. 2021. “Secondary Histiocytic Sarcoma with BRAFV600E Mutation Responsive to MAPK‐targeted Therapy Presenting with Recurrence with MTOR Mutation Responsive to MTOR‐targeted Therapy.” Pediatric Blood & Cancer 68 (10): 1–3. doi:10.1002/pbc.29166.